Cymetra: A treatment option for refractory ulcers

Wounds

Volumn 16, Issue 12, 2004, Pages 359-363

  Levy, Daniel ^a   Banta, Meggan R ^a   Charles, Carlos A ^a   Eaglstein, William H ^b   Kirsner, Robert S ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b IVAX Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN; CYMETRA; DERMATOLOGICAL AGENT; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPRESSION THERAPY; DEBRIDEMENT; EOSINOPHILIC FASCIITIS; FEMALE; HUMAN; MALE; POSTOPERATIVE PERIOD; PYODERMA GANGRENOSUM; RETROSPECTIVE STUDY; SEGMENTED HYALINIZING VASCULITIS; SKIN ULCER; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULITIS; VEIN INSUFFICIENCY;

EID: 12444318572     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Eaglstein WH, Falanga V. Chronic wounds. Surg Clin North Am 1997;77(3):689-700.
2. Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: Financial, social, and psychologic implications. J Am Acad Dermatol 1994;31(1):49-53.
3. Sclafani AP, Romo T III, Jacono AA. Rejuvenation of the aging lip with an injectable acellular dermal graft (Cymetra). Arch Facial Plast Surg 2002;4(4):252-7.
4. Homicz MR, Watson D. Review of injectable materials for soft tissue augmentation. Facial Plast Surg 2004;20(1):21-9.
5. Banta MN, Eaglstein WH, Kirsner RS. Healing of refractory sinus tracts by dermal matrix injection with Cymetra. Dermatol Surg 2003;29(8):863-6.
6. Takahashi PY, Kiemele LJ, Jones JP Jr. Wound care for elderly patients: Advances and clinical applications for practicing physicians. Mayo Clin Proc 2004;79(2):260-7.
7. Callen JP. Pyoderma gangrenosum. Lancet 1998;351(9102)581-5.
8. Weiman TJ. Efficacy and safety of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic venous ulcers: A pilot study. WOUNDS 2003;15(8):257-64.
9. Jiang WG, Harding KG. Enhancement of wound tissue expansion and angiogenesis by matrix-embedded fibroblast (Dermagraft), a role of hepatocyte growth factor/scatter factor. Int J Mol Med 1998;2:203-10.
10. Sclafani AP, Romo T III, Jacono AA, et al. Evaluation of acellular dermal graft in sheet (AlloDerm) and injectable (micronized AlloDerm) forms for soft tissue augmentation: Clinical observations and histological analysis. Arch Facial Plast Surg 2000;2:130-6.
11. Agag RL, Granick MS, Omidi M, Catrambone J, Benevenia J. Neurosurgical reconstruction with acellular cadaveric dermal matrix. Ann Plast Surg 2004;52(6):571-7.
12. Woodyard JG, Greenwell H, Hill M, et al. The clinical effect of acellular dermal matrix on gingival thickness and root coverage compared to coronally positioned flap alone. J Periodontol 2004;75(1):44-56.
13. Buinewicz B, Rosen B. Acellular cadaveric dermis (AlloDerm): A new alternative for abdominal hernia repair. Ann Plast Surg 2004;52(2):188-94.
14. Embil JM, Papp K, Sibbald G, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: An open-label clinical evaluation of efficacy. Wound Repair Regen 2000;8(3):162-8.
15. Harrison-Balestra C, Eaglstein WH, Falabella AF, Kirsner RS. Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers: A retrospective series. Dermatol Surg 2002;28(8):755-60.